Sexuall Transmitted Disease Chlamydia trachomatis, Neisseria gonorrhoeae, Treponema pallidum, Mycoplasma genitalium, doxycycline
Conditions
Interventions
Study group: Single 200 mg dose of Vibramycin 2 to 24 hours prior to sexual intercourse, administered each time of sexual intercourse
Control group: Single 200 mg dose of Vibramycin within 72 hours af
Sponsors
Mizushima Daisuke
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: The applicant must meet all of the following conditions (1) through (4). (1) Persons aged 18 or older who are attending our sexual health (SH) clinic. (2) Persons with a history of sexually transmitted infections while attending the SH clinic. (3) Those who are on PrEP (pre-exposure prophylaxis) for HIV (4) Persons who have given written consent to participate in the study.
Exclusion criteria
Exclusion criteria: (1) Those who are allergic to any of the study drugs (2) Other cases in which the physician in charge determines that participation in the study is inappropriate.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| the occurrence of a first STI (gonorrhoea, chlamydia, or syphilis) during the follow-up period. | — |
Secondary
| Measure | Time frame |
|---|---|
| The occurrence of a first each sexually transmitted infection (chlamydia, gonorrhea, syphilis, genitalium). Incidence rate of any of chlamydia, gonorrhea, or syphilis. Incidence rate of each sexually transmitted infection (chlamydia, gonorrhea, syphilis, and genitalium). Adherence to medications. Percentage of adverse events. | — |
Contacts
Public ContactDaisuke Mizushima
National Center for Global Health and Medicine
Outcome results
None listed